A PD‐L1 siRNA‐Loaded Boron Nanoparticle for Targeted Cancer Radiotherapy and Immunotherapy

• DOI: 10.1002/adma.202419418
• Publication Date: 2025-02-16T14:26:56Z
• Authors: Shaohui Deng; Lijun Hu; Guo Chen; Jujian Ye; Zecong Xiao; Tianwang Guan; Shuai Guo; Wei Xia; Du Cheng; Xiaochun Wan; Ke Cheng; Caiwen Ou
• Keywords: Cancer Immunotherapy

Although the combination of radiotherapy and immunotherapy is regarded as a promising clinical treatment strategy, numerous trials have failed to demonstrate synergistic effects. One key reasons that conventional radiotherapies inevitably damage intratumoral effector immune cells. Boron Neutron Capture Therapy (BNCT) precise selectively kills tumor cells while sparing adjacent normal cells, by utilizing 10B agents neutron irradiation. Therefore, combinational BNCT-immunotherapy holds promise for achieving more effective Here it develops 10B-containing polymer self-assembled with PD-L1 siRNA form 10B/siPD-L1 nanoparticles BNCT-immunotherapy. Unlike antibodies, can inhibit intracellular upregulated BNCT, activating T-cell immunity also suppressing DNA repair. This enhance BNCT-induced damage, promoting immunogenic cell death (ICD) further amplifying antitumor effect. The results demonstrated BNCT using precisely killed T induced potent response, inhibiting distal metastatic tumors.